In Vivo Activity Articles & Analysis
2 news found
In vivo data presented at the SITC annual meeting highlight the potential of T-knife’s lead product candidate TK-8001, a TCR engineered T cell therapy (TCR-T) that is being developed to treat MAGE-A1 positive solid tumors. ...
The advancement of ART24 into the Phase 1 clinical trial was based on its favorable profile exhibited in pre-clinical safety testing, as well as its demonstration of potent and selective in vitro and in vivo activity against C. difficile and associated toxins. The Phase 1 clinical trial is evaluating ART24 for safety, tolerability and pharmacokinetics in a ...